In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocera Therapeutics Inc.

Division of Mallinckrodt PLC
www.ocerainc.com

Latest From Ocera Therapeutics Inc.

Bridging The Gap: Cyclenium Pharma

Emerging Company Profile: Cyclenium Pharma spoke with Scrip about macrocyclic drug discovery, which covers the molecular space between traditional small molecules and large bio-molecules, to capture the pharmacological properties of larger peptides/proteins in metabolically stable small molecules and proven in a broad range of target classes.

Infectious Diseases StartUps and SMEs

Biopharma Quarterly Deal-making Statistics, Q4 2017

Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.

Deals Market Intelligence

Deals Shaping The Medical Industry, December 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.

Deals BioPharmaceutical

Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results

Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.

Sales & Earnings Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mallinckrodt PLC
  • Senior Management
  • Linda S Grais, MD, Pres. & CEO
    Michael Byrnes, CFO
    Stan Bukofzer, MD, CMO
  • Contact Info
  • Ocera Therapeutics Inc.
    Phone: (650) 475-0158
    555 Twin Dolphin Dr.
    Ste. 615
    Redwood City, CA 94065
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register